论文部分内容阅读
目的:探讨喘可治注射液辅助治疗慢性阻塞性肺疾病(COPD)急性加重期的临床疗效。方法:纳入我院2014年8月到2015年8月收治的COPD急性加重期患者64例,随机分为观察组32例和对照组32例,对照组患者给予常规,观察组在对照组治疗的基础上加以喘可治注射液辅助治疗,比较两组治疗后的效果。结果:观察组治疗总有效率为84.38%(27/32),较对照组71.88%(23/32)显著提高(P<0.05);观察组治疗后血清IL-6指标、IL-8以及INF-α较对照组改善明显(P<0.05)。结论:喘可治注射液辅助辅助治疗COPD急性加重期患者可显著改善患者临床症状和体征,提高治疗效果,有临床推广价值。
Objective: To investigate the clinical efficacy of Chuankezhi injection in the treatment of acute exacerbation of chronic obstructive pulmonary disease (COPD). Methods: Sixty-four patients with acute exacerbation of COPD admitted to our hospital from August 2014 to August 2015 were randomly divided into observation group (32 cases) and control group (32 cases). Patients in the control group On the basis of adjuvant treatment of Chuankezhi injection, the effect of the two groups after treatment was compared. Results: The total effective rate of the observation group was 84.38% (27/32), which was significantly higher than that of the control group (71.88%, 23/32) (P <0.05). The levels of IL-6, IL-8 and INF -α improved significantly compared with the control group (P <0.05). Conclusion: Chuankezhi injection adjuvant therapy for patients with acute exacerbation of COPD can significantly improve the clinical symptoms and signs of patients, improve the therapeutic effect, the clinical value of the promotion.